FTO partially promoted the anti-tumor properties of ccRCC by decreasing m6A levels of PPARγ coactivator (PGC)‐1α mRNA transcripts and therefore increasing PGC-1α expression[40]. The gene discussed is FTO; the disease is nonpapillary renal cell carcinoma.